Related Experiment Video
Updated: Feb 1, 2026
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human
Jonathan G Pol1, Sergio A Acuna2, Beta Yadollahi3
1McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Abstract:
Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No severe adverse events were observed. Boosting with MG1-MAGEA3 induced an expansion of hMAGE-A3-specific CD4+ and CD8+ T-cells with the latter peaking at remarkable levels and persisting for several months. T-cells reacting against epitopes fully conserved between simian and human MAGE-A3 were identified. Humoral immunity was demonstrated by the detection of circulating MAGE-A3 antibodies. These preclinical data establish the capacity for the Ad:MG1 vaccination to engage multiple effector immune cell populations without causing significant toxicity in outbred NHPs. Clinical investigations utilizing this program for the treatment of MAGE-A3-positive solid malignancies are underway (NCT02285816, NCT02879760).
Insights
This study shows that a prime-boost vaccination using an adenoviral vector and Maraba virus expressing MAGE-A3 is safe and effective in non-human primates. The vaccine successfully generated robust T-cell and antibody responses against cancer cells.
Area of Science:
- Immunology
- Oncolytic Virology
- Preclinical Cancer Research
Background:
- Advanced solid tumors often resist current immunotherapies.
- Developing novel cancer vaccines is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the safety and immunogenicity of a novel prime-boost vaccination strategy in non-human primates.
- To evaluate the potential of an oncolytic viral vaccine expressing MAGE-A3 for cancer treatment.
Main Methods:
- Non-human primates (Macaca fascicularis) received an adenoviral prime followed by a Maraba MG1 rhabdovirus boost, both expressing human MAGE-A3.
- Safety was monitored for adverse events.
- Immunogenicity was assessed by measuring T-cell responses (CD4+ and CD8+) and antibody production.
Main Results:
- The Ad:MG1 vaccination was well-tolerated, with no severe adverse events observed.
- Boosting induced significant expansion and long-term persistence of MAGE-A3-specific CD4+ and CD8+ T-cells.
- Immune responses targeted conserved epitopes, and humoral immunity (antibodies) was detected.
Conclusions:
- The Ad:MG1 vaccination strategy is safe and immunogenic in non-human primates.
- This approach effectively engages multiple immune cell populations against MAGE-A3.
- Clinical trials are ongoing for MAGE-A3-positive solid tumors.
Related Concept Videos
01:51Vaccinations
01:11Clinical Trials: Overview
01:12Trial and Error and Algorithm
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
00:50What are Viruses?
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...